Shots:
Under the terms of the agreement, Aclaris granted Pediatrix the exclusive rights to develop, manufacture & commercialize ATI-1777 in China, Macau, Taiwan & Hong Kong whereas Aclaris will retain the rights of ATI-1777 across the world
Aclaris will receive a $5M upfront payment & is eligible to receive up to $91M in development, regulatory & commercialization milestones along with low-to-high single-digit tiered royalties in Greater China
ATI-1777 is a soft JAK 1/3 inhibitor with the potential to minimize systemic toxicities in patients with atopic dermatitis
Ref: Globenewswire | Image: Aclaris
